Glenmark Pharmaceuticals Ltd.
Snapshot View

386.75 -7.80 ▼-2.0%

25 May 2022, 04:01:00 PM
Volume: 22,264

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarkpharma.com
Market Cap 10,912.85 Cr.
Enterprise Value(EV) 13,070.69 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 36.15 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 10.70 Trailing Twelve Months Ending 2021-12
Industry PE 28.07 Trailing Twelve Months Ending 2021-12
Book Value / Share 315.45 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.23 Calculated using Price: 386.75
Dividend Yield 0.65 Period Ending 2021-03
No. of Shares Subscribed 28.22 Cr. 282,168,156 Shares
FaceValue 1
Company Profile

Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.

India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.

Business area of the company

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Awards

  • It was conferred with the Pharmaexcil Gold Award for New Chemical Entities 2015.
  • SCRIP crowned Glenmark as the ‘Best Pharma Company in Emerging markets’ and ‘Best Overall Pipline’ at SCRIP Awards 2011 in London. 
  • Swiss Ambassador's award for Exceptional Innovation - 2012.
  • It received the Bombay Chamber of Commerce and Industry Civic Award 2014. 
  • It was conferred with the prestigious Golden Peacock Management Award - 2015 for its Environment Sustainability initiatives at the Goa manufacturing facility.

Milestone

2010

  • Glenmark Pharmaceuticals has entered into a settlement and license agreement with Sepracor Inc to market generic Eszopiclone tablets.

2012

  • Forest Laboratories and Glenmark Sign Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions.

2014 

  • Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitor.

2015

  • Glenmark announced the Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. In the same year, Glenmark received approval for generic Seretide in Russia.

2016 

  • Glenmark launched ezetimibe, the first and only generic version of Zetia in the United States for the treatment of high cholesterol.

2019

  • Glenmark Pharmaceuticals and Mankind Pharmaceuticals have inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
  • Glenmark Pharmaceuticals’ partner -- Seqirus Pty (Seqirus) has received marketing approval for Ryaltris from the Therapeutic Goods Administration (TGA), Australia.

2020

  • Glenmark Pharmaceuticals has launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
  • Glenmark Pharmaceuticals has launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI). 
  • Glenmark Pharmaceuticals has launched of a Single Inhaler Triple Therapy AIRZ-FF.
  • Glenmark Pharmaceuticals has entered into an agreement with Hindustan Unilever (HUL) for divestment of its VWash brand and other extensions.
  • Glenmark Pharmaceuticals’ Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma) for commercializing its novel nasal spray Ryaltris in the US.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.98%
1 Week
-4.76%
1 Month
-9.37%
3 Month
-14.47%
6 Month
-26.98%
1 Year
-35.69%
2 Year
+9.93%
5 Year
-36.80%
10 Year
+9.81%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 24.33 18.99 8.79 27.46 27.31 16.67 17.21 13.32 14.81
Return on Capital Employed (%) 17.67 15.04 12.40 18.53 20.54 14.77 16.47 14.04 15.30
Return on Assets (%) 10.40 7.51 2.58 8.52 11.33 7.40 7.98 6.17 7.11

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 2,763 2,983 1,783 3,630 4,493 5,163 5,605 6,071 7,065 8,661
Non Curr. Liab. 1,625 1,967 2,749 1,499 3,258 2,824 2,280 3,033 2,804 1,243
Curr. Liab. 2,201 2,949 3,777 3,999 2,703 3,288 4,021 4,126 4,201 4,784
Minority Int. 24 13 0 0 0 0 0 0 0 339
Equity & Liab. 6,614 7,912 8,309 9,128 10,453 11,275 11,906 13,229 14,069 15,027
Non Curr. Assets 2,887 3,150 2,978 3,224 3,578 4,286 5,209 6,425 6,709 6,953
Curr. Assets 3,727 4,763 5,331 5,904 6,875 6,989 6,697 6,804 7,360 8,073
Misc. Exp. not W/O
Total Assets 6,614 7,912 8,309 9,128 10,453 11,275 11,906 13,229 14,069 15,027

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 4,969 5,945 6,681 7,562 9,079 9,074 9,865 10,641 10,944 12,146
Other Income 11 11 7 20 37 91 208 160 50 68
Total Income 4,980 5,956 6,688 7,582 9,117 9,166 10,074 10,801 10,994 12,214
Total Expenditure -3,954 -4,854 -5,467 -6,125 -7,043 -7,459 -8,280 -8,943 -8,860 -9,765
PBIDT 1,026 1,102 1,221 1,457 2,074 1,707 1,794 1,858 2,135 2,448
Interest -160 -189 -190 -179 -237 -286 -335 -377 -353 -295
Depreciation -127 -217 -300 -234 -264 -302 -326 -417 -444 -466
Taxation -111 -151 -334 -301 -383 -315 -376 -320 -412 -454
Exceptional Items -187 -81 167 33 45 -178
PAT 628 546 209 743 1,109 804 925 776 970 1,055
Minority Interest -8 -3 0 0 0 0 0 0 -35
Share Associate
Other Related Items
Consolidated Net Profit 620 542 210 743 1,109 804 925 776 970 1,020
Adjusted EPS 23 20 8 26 39 28 33 28 34 36

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 804 648 854 482 345 657 1,648 1,324 1,392 1,131
Cash Fr. Inv. -278 -464 -368 -540 -880 -712 -1,013 -699 -784 -675
Cash Fr. Finan. -361 195 -98 199 699 543 -469 -739 -445 -442
Net Change 165 379 388 141 163 488 166 -114 164 14
Cash & Cash Eqvt 320 605 795 764 857 1,056 1,233 936 1,110 1,138

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 46.62 46.62 46.63 46.63 46.63 46.63 46.65 46.65 46.65
Public 53.38 53.38 53.37 53.37 53.37 53.37 53.35 53.35 53.35
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP 500 mg
Fri, 20 May 2022
U.S. FDA Inspection At The Company''s Monroe North Carolina (USA) Facility
U.S. FDA inspection at the Companys Monroe North Carolina (USA) Facility
Fri, 20 May 2022
U.S. FDA Inspection At The Company''s Goa India Facility
U.S. FDA inspection at the Companys Goa India Facility

Technical Scans View Details

Wed, 25 May 2022
Closing Below Previous Low Closing Below Previous Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 218,615.41 911.15 +0.1%
Divi's Laboratories Ltd. 93,410.43 3,518.70 -3.9%
Cipla Ltd. 78,373.92 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. 71,774.48 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. 50,694.88 3,525.75 -2.9%
Gland Pharma Ltd. 45,552.31 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. 44,253.16 2,615.30 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.92 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 31.55 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 31.14 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.89 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 44.73 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 37.59 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.30 2,615.30 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.23 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 7.96 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 3.76 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.16 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 6.36 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.84 2,615.30 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 0.10 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,615.30 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,615.30 +0.9%